Peripheral Drug Eluting Balloons Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afri

Peripheral Drug Eluting Balloons Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global peripheral drug eluting balloons (DEBs) market has witnessed significant growth over the past decade, reaching a market value of US$ 950 million in 2024. The market is poised for continued expansion, with an anticipated 9.56% CAGR, expected to reach a valuation of US$ 1800 million by the end of 2031.

The Growing Challenge of Peripheral Vascular Disease

Peripheral vascular disease, characterized by the narrowing or obstruction of blood arteries that supply the limbs, is a global health concern primarily caused by the accumulation of fatty plaques in arteries. The market for peripheral drug eluting balloons is expanding due to the increasing incidence of peripheral arterial disease (PAD) worldwide.
• According to the National Institutes of Health, in 2020, lifestyle changes, smoking, pollution, and other factors contributed to the condition claiming the lives of 20% of individuals aged 55 and older.

The prevalence of PAD and the need for interventional cardiology care are on the rise, making angioplasty, often performed using DEBs, the preferred treatment for long-term PAD.
• The Centers for Disease Control and Prevention (CDC) reported in 2021 that approximately 8.5 million people in the U.S. had PAD, with 12% to 20% of individuals over 60 years of age affected.

Driving Forces Behind the Rapid Adoption of Peripheral Drug Eluting Balloons

Rising Aging Population and Increasing Vascular Diseases: The elderly population is more susceptible to vascular diseases due to natural aging processes, contributing to the growing demand for peripheral vascular surgeries. The increased use of stents during surgeries among the elderly, coupled with improved life expectancies, has created significant opportunities for manufacturers.
• According to the United Nations, middle-income countries are expected to experience rapid growth in the number of older individuals between 2015 and 2030, with projections indicating a 64% increase in India and a 71% increase in China.
• The U.S. is also experiencing substantial demographic changes, with the population of Americans aged 65 and older expected to more than double from 46 million to over 98 million by 2060, according to the Population Reference Bureau in 2023.

Challenges Faced by Market Players

High Product Cost and Limited Clinical Evidence: The cost of peripheral DEBs, including the device and drug, can be relatively high compared to traditional treatment options such as angioplasty or stenting. Higher upfront costs may deter adoption, especially in regions with limited healthcare budgets or reimbursement constraints. The cost factor remains a significant consideration for healthcare providers and payers when evaluating DEBs against alternative treatments.

Although DEBs have demonstrated promising clinical results, the market requires robust long-term clinical evidence and large-scale randomized controlled trials to establish their efficacy and superiority over alternative treatments. The limited availability of long-term data on patient outcomes can impact the confidence of healthcare providers in adopting DEBs as the standard treatment option.

Country-wise Insights

United States: A Prominent Market for Peripheral Drug Eluting Balloons

The U.S. peripheral DEBs market is poised for substantial growth due to advanced product development and the increasing prevalence of peripheral artery diseases in the country. The rising prevalence is driven by factors such as an aging population, high rates of diabetes, obesity, and lifestyle-related risks like smoking.
• The U.S. Department of Health & Human Services reported in 2023 that approximately 6.5 million people aged 40 and older in the U.S. are living with PAD.

China: A Lucrative Market for Peripheral Drug Eluting Balloon Manufacturers

China offers a promising market for DEB manufacturers, supported by favorable government policies and reimbursement support. The Chinese government's healthcare reforms and investments aim to improve healthcare access, enhance reimbursement schemes, and reduce patient financial burdens. Favorable reimbursement policies have incentivized healthcare providers to adopt DEBs on a larger scale.
• Chinese medical device manufacturers have engaged in collaborations with international companies to access advanced technologies and expertise, facilitating the introduction of advanced DEB products to the Chinese market.

Germany: Growing Demand for Peripheral Drug Eluting Balloons

Germany's advanced healthcare infrastructure, equipped with well-established hospitals, specialized medical centers, and skilled healthcare professionals, fosters an environment conducive to the adoption of innovative medical technologies like DEBs. Increasing awareness and education about peripheral artery disease and available treatment options have contributed to greater acceptance and adoption of DEBs in Germany.

Key Companies in the Market
• Abbott Laboratories
• Boston Scientific Corporation
• Cook Medical Inc.
• MicroPort Scientific Corporation (Endovastec™)
• Medtronic Plc.
• Cardinal Health, Inc.
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Becton, Dickinson and Company
• W. L. Gore & Associates Inc.
• Getinge AB
• Terumo Corp
• Kyoto Medical Planning Co Ltd
• iVascular S.L.U
• AMG International GmbH
• ENDOCOR GmbH
• Meril Life Sciences Pvt. Ltd.
• Nano Therapeutics Pvt Ltd
• Koninklijke Philips N.V.
• REVA Medical

Key Segments of Peripheral Drug Eluting Balloons Industry Research

Drug Coating:
• Paclitaxel Drug Coating
• Sirolimus drug Coating
• Others

Indication:
• Peripheral Arterial Disease
• Peripheral Aneurysms
• In-Stent Restenosis
• Others

Artery Type:
• Carotid Arteries
• Fem-Pop Arteries
• Iliac Arteries
• Infrapop Arteries

End User:
• Hospitals
• Ambulatory Surgical Centers/Outpatients
• Cardiac Catheterization Labs

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. The Delivery Timelines - 5 working days.